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Background: Potential drug–drug interactions (PDDIs) in patients with cancer are common, but have not previously been
quantified for oral anticancer treatment. We assessed the prevalence and seriousness of potential PDDIs among ambulatory
cancer patients on oral anticancer treatment.
Methods: A search was conducted in a computer-based medication prescription system for dispensing oral anticancer drugs to
outpatients in three Dutch centres. Potential drug–drug interactions were identified using electronic (Drug Interaction Fact
software) and manual screening methods (peer-reviewed reports).
Results: In the 898 patients included in the study, 1359 PDDIs were identified in 426 patients (46%, 95% confidence interval
(CI)¼ 42–50%). In 143 patients (16%), a major PDDI was identified. The drug classes most frequently involved in a major PDDI were
coumarins and opioids. The majority of cases concerned central nervous system interactions, PDDIs that can cause gastrointestinal
toxicity and prolongation of QT intervals. In multivariate analysis, concomitant use of more drugs (odds ratio (OR)¼ 1.66, 95%
CI¼ 1.54–1.78, Po0001) and genito-urinary cancer (OR¼ 0.25, 95% CI¼ 0.12–0.52, Po0001) were risk factors.
Conclusion: Potential drug–drug interactions are very common among cancer patients on oral cancer therapy. Physicians and
pharmacists should be more aware of these potential interactions.
Drug–drug interactions in patients with cancer are common, and
most drug–drug interactions can cause considerable adverse drug
reactions (ADRs) (Ko¨hler et al, 2000). In the general population,
it has been reported that 20–30% of all ADRs are caused by drug–
drug interactions (Ko¨hler et al, 2000). Drug–drug interactions are
estimated to be the cause of death in B4% of cancer patients
(Buajordet et al, 2001). Patients treated systemically for cancer are
particularly at risk for drug–drug interactions. Typically, patients
*Correspondence: Dr RWF van Leeuwen; E-mail: r.w.f.vanleeuwen@erasmusmc.nl
This study was presented at the 37th ESMO Annual Meeting (Vienna, Austria, 28 September to 2 October 2012, #1402).
Received 16 November 2012; revised 16 January 2013; accepted 17 January 2013; published online 14 February 2013
& 2013 Cancer Research UK. All rights reserved 0007 – 0920/13
FULL PAPER
Keywords: chemotherapy; potential drug–drug interactions; oncology; pharmacology; risk factors
British Journal of Cancer (2013) 108, 1071–1078 | doi: 10.1038/bjc.2013.48
www.bjcancer.com |DOI:10.1038/bjc.2013.48 1071
with cancer receive a high number of drugs concomitantly,
including cytotoxic agents, hormonal agents, targeted agents, and
supportive care agents among medication prescribed to treat
comorbidities. An additional problem is that the mean age of
cancer patients is increasing. Older patients generally have more
comorbidities for which they also receive drug treatment (Yancik
and Ries, 2000). The risk for drug–drug interactions in elderly
cancer patients is further increased because of altered age- and
comorbidity-related physiologic changes (e.g., altered drug absorp-
tion due to mucositis or altered excretion due to renal and hepatic
impairment) (Scripture and Figg, 2006).
Here, a potential drug–drug interaction (PDDI) was defined as
the occurrence of a potentially harmful combination of prescribed
drugs in a given patient, rather than the occurrence of an actual
adverse event for a patient.
In clinical practice, PDDIs can be distinguished as pharmaceu-
tical, pharmacokinetic, and pharmacodynamic interactions
(Scripture and Figg, 2006). Pharmaceutical PDDIs occur for
instance when two chemically or physically incompatible com-
pounds are combined (e.g., cisplatin and mesna; Verschraagen
et al, 2003). Pharmacokinetic interactions refer to an influence on
the absorption, distribution, metabolism, or elimination of the
drug itself or a combination of drugs. A common pharmacokinetic
interaction concerns drugs metabolised by the cytochrome P450
(CYP) enzymes. By inhibition or induction of CYP iso-enzymes,
blood and tumour concentrations, antitumoural effects, and
toxicities of specific anticancer therapies may be altered. Other
pharmacokinetic interactions may result from, that is, inhibition of
the ABCB1 efflux-transporter (or P-glycoprotein); by altering the
activity of ABCB1, the bioavailability of anticancer drugs may be
influenced. Pharmacodynamic drug interactions usually occur
when two or more drugs have a similar mechanism of action. The
effect can be synergistic, additive, or antagonistic. Pharmacody-
namic drug interactions can be beneficial (e.g., enhanced
pharmacologic effects with fluorouracil and leucovorin), but may
also be potentially harmful (e.g., ototoxicity with furosemide and
cisplatin; Brummett, 1981).
In general medicine, the prevalence of PDDIs and their
determinants has been evaluated in several studies (Egger et al,
2003; Geppert et al, 2003; Glintborg et al, 2005). By contrast, data
on the prevalence of PDDIs with anticancer drugs are scarce. Two
studies, conducted in ambulatory cancer patients, found that
27–58% of all patients had at least one PDDI (Riechelmann et al,
2007; van Leeuwen et al, 2011). Determinants for PDDIs were an
increasing number of drugs, the use of OTC drugs, type of
medication (drugs to treat comorbid conditions only), and the
presence of brain tumours. However, these studies included only
outpatients receiving intravenous anticancer treatment at a day-
treatment facility (Riechelmann et al, 2007; van Leeuwen et al,
2011). A retrospective database study, involving cancer patients on
oral anticancer therapy, found that 5% of all patients had at least
one potentially interacting drug combination (Ko et al, 2012).
In the last decade, the availability and use of oral anticancer
agents has increased dramatically. In comparison with parenteral
treatment, the administration of oral agents is usually believed to
be more convenient for the patient (Aisner, 2007). However, due to
chronic use and the fact that most anticancer drugs are
metabolised by CYPs (Scripture and Figg, 2006), patients on oral
anticancer agents are at considerable risk for PDDIs. Moreover, a
relative lack of collaboration between medical oncologists,
pharmacists, and general practitioners, and the fact that compu-
ter-based medication prescription systems in hospitals and
community pharmacies are usually not connected leads to PDDIs
frequently going unnoticed (Aisner, 2007).
At present, epidemiological data regarding harmful PDDIs
during oral anticancer therapy are scarce in the literature.
Therefore, the aim of this study was to investigate the prevalence
of PDDIs among ambulatory cancer patients on oral anticancer
treatment, with the primary intent to create awareness among
oncologists and pharmacists regarding the risk of potentially
harmful drug–drug interactions. The secondary objective was to
obtain more insight into possible determinants for the occurrence
of these PDDIs.
MATERIALS AND METHODS
Study design and patients. A multicentre cross-sectional study of
the prevalence of PDDIs was conducted in ambulatory cancer
patients treated with oral anticancer drugs in three Dutch centres:
the Maastricht University Medical Center (Maastricht), St.
Radboud University Medical Centre (Nijmegen), and Deventer
Teaching Hospital (Deventer). All ambulatory patients with the
diagnosis of a solid tumour or a haematological malignancy, who
were receiving one of more oral anticancer therapies (with or
without additional intravenous anticancer drugs), were included in
the study. Exclusion criteria were (i) the use of (oral) experimental
trial agents, (ii) age o18 years, and (iii) the use of oral anticancer
drugs for non-malignant diseases. This study was registered under
number ISRCTN01739090, and was approved by the medical
ethics boards of all three participating institutes.
Procedures. A retrospective search was conducted in the compu-
ter-based medication prescription system of the hospital pharmacy
in these three centres for the dispensing of oral anticancer drugs to
outpatients over a period of 12 months (between 1 October 2010
and 1 October 2011). Medications were classified into three groups;
‘anticancer drugs’, ‘supportive care drugs’, and ‘drugs to treat
additional diseases/comorbidities’. Anticancer drugs were defined
as oncolytic drugs (Anatomical Therapeutic Chemical code (ATC-
code) L01) and antihormonal agents (ATC-code L02). In addition,
data on supportive care and co-medication were collected using the
same computer-based medication prescription system of the
hospital pharmacy. Supportive care drugs included antiemetic
and analgesic drugs. Drugs for chronic and incidental use (e.g.,
dexamethasone during chemotherapy) were included in this study
as long as they were used concurrently as was defined by Tobi et al
(2007). Information concerning type of cancer and comorbidities
was collected by medical chart review. In this study, comorbidities
were defined as all other diseases an individual patient might have,
other than the primary disease of interest (cancer).
Renal function [creatinine] and liver function parameters
(aspartate aminotransferase (AST), alanine aminotransferase
(ALT), and g-glutamyltransferase (g-GT)) were extracted from
the laboratory database of the hospital while an individual patient
was receiving an oral anticancer agent. Laboratory abnormalities
were defined as an increase of 450% above the upper limit of
normal (upper normal limits in all three medical centres:
ASATp35 U/L, ALATp40 U/L, g-GTp44 U/L, creatininep99
mmol/L).
Potential drug–drug interactions between drugs and over-the-
counter (OTC) medication were not studied. When a drug
formulation contained two or more pharmacologically active
ingredients each drug was counted individually in the analysis
(e.g., tramadol/acetaminophen). However, when a patient was
taking the same medication in more than one formulation (e.g.,
long- and short-acting morphine) the drug was counted only once.
In this study, we have identified drug–drug combinations,
within the same patient, for drugs that are known for having
interacting effects, rather than the occurrence of an actual adverse
event in an individual patient. Potential drug–drug interactions
were identified by using the Drug Interaction Facts software (Facts
and Comparisons, version 4.0, 2006), which is a commonly used
and reputable source. It has been shown to have an accuracy of
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over 95% in detecting interactions (Barrons, 2004). Drug
Interaction Facts software classifies interactions by the level of
severity and the level of scientific evidence. A detailed classification
of level of severity and scientific evidence is shown in Figure 1.
The medication regimen of each patient was also screened for:
1. Drug combinations with potential QT-interval prolongation
and/or torsades de pointes inducing properties using the
Arizona CERT system list 1 (risk of torsades) and list 2
(possible risk of torsades) (Scientific Advisory Board of the
Arizona Centre for Education and Research on Therapeutics
(CERT)). Because of the potentially severe consequences, all
drug combinations with risk for QT prolongation were classified
as major (QT interaction). The QT-interval prolonging
potential of drugs is generally well documented and QT
interactions were classified as ‘probable’ as was defined in
Figure 1.
2. Drugs associated with an increased risk of falling (central
nervous system (CNS)-depressant agents). First, the medication
regimen of each patient was manually screened for CNS-
depressant agents by using handbooks and peer-reviewed
reports on scientific evidence (Leipzig et al, 1999; Lord et al,
2003; Tinetti, 2003; Hartikainen et al, 2005; Gralow et al, 2009;
Woolcott et al, 2009). A combination of two CNS-depressant
agents was counted as one interaction and defined as CNS
interaction in the analysis. All CNS interactions were classified
as moderate. The CNS-depressant potential of drugs is
described in the literature, and CNS interactions were classified
as ‘probable’ as was defined in Figure 1.
3. Drug combinations between non-steroidal anti-inflammatory
drugs (NSAIDs) and corticosteroids, anticoagulants, aspirin,
bisphosphonates, or selective serotonin reuptake inhibitors
(SSRIs). These combinations were defined as a gastrointestinal
(GI) interaction and were identified by using the Drug
Interaction Facts software and peer-reviewed reports on
scientific evidence (Piper et al, 1991; Lanza, 1998; Singh,
Rosen Ramey (1998)). The GI interactions may increase the risk
of GI bleeding. Due to the potentially severe consequences all GI
interactions were classified as major. The GI interactions are
generally well documented, and were classified as ‘probable’ as
was defined in Figure 1.
A PDDI was only counted in the analysis when an ‘anticancer
agent’ or a ‘supportive care drug’ was involved; thus, PDDIs
resulting from the treatment of comorbidities were disregarded.
Interactions of minor severity, being clinically not relevant, were
not included in the analysis.
Statistical analysis. To compute patient demographics, cancer
type, comorbidities, number of drugs used per patient, laboratory
abnormalities, and drug interaction characteristics (severity,
scientific evidence, and mechanism), descriptive statistics were
used. Subsequently, univariate and multivariate binary logistic
regression analyses were performed to identify the potential risk
factors for the occurrence of PDDIs. The occurrence of at least one
DDI per patient was called the dependent variable. Predictor
variables tested included age, number of drugs, presence of
comorbidities (yes/no), cancer type, treatment type, solid tumour
or haemato-oncology disease and laboratory abnormalities. Gender
was not included as a predictor variable as certain cancer types
only occur in men or women. The largest group per predictor
variable was taken as the reference (Ref.) for binary or nominal
variables. In the multivariate analysis predictor, variables with
univariate P-values o0.1 were included. Predictor variables in the
multivariate analysis with a P-value of o0.05 were considered
statistically significant. The data were adjusted for confounders and
effect modifiers. Data were collected and analysed in SPSS version
15.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Patient. A total of 898 patients were included in this study, with a
median age of 61 years (range 18–95 years), of which 58% were
female. The median number of drugs used per person was five
(range 1–24 drugs). Demographic characteristics are listed in
Table 1. In 898 patients, a total of 31 different oral anticancer drugs
were identified as stated in Table 2.
Drug interactions. In total, 1359 PDDIs were identified in 426
patients (46%, 95% CI¼ 42–50%; Figure 2). In 143 patients (16%)
at least one major PDDI was identified. Of all PDDIs, 15% and
83% were classified as major and moderate PDDIs, respectively. In
14% of all PDDIs, anticancer drugs were involved. A pharmaco-
dynamic PDDI was found in 86% of all cases. The majority of cases
concerned CNS interactions (n¼ 848), GI interactions (n¼ 97),
and QT interaction (n¼ 45). Most PDDIs (86%) were supported
by level 2 (probable) or level 3 (suspected) scientific evidence. A
stratification of the identified PDDIs by ‘level of severity’, ‘level of
scientific evidence’, and ‘mechanism of drug interaction’ is listed in
Figure 2.
Potential drug–drug interactions involving anticancer drugs and
supportive care agents are listed in Table 3. As the variety of drug
classes is diverse, only PDDIs with potentially major consequences
are reported. The drug classes most commonly involved in major
PDDIs were coumarins and opioids. The QT interactions and GI
interactions were also observed frequently.
Risk factors. All patients were included in the binary logistic
regression analysis. In the univariate analysis, the number of drugs,
treatment type, cancer type, and the presence of comorbidities
were associated with higher risk for PDDIs. No statistically
significant association was found for age (P¼ 0.124), tumour type
(solid/non-solid malignancy; P¼ 0.327), or laboratory abnormal-
ities (P¼ 0.295). Results of the univariate and multivariate binary
logistic regression analyses are listed in Table 4. After adjustment
for confounders, the number of drugs (odds ratio (OR) 1.66
Classification by:
Level of severity: Level of scientific evidence:
1. Major: life-threatening or permanent damage
2. Moderate: deterioration of patient’s status, treatment is required
3. Minor: bothersome or little effect
1. Established: proven to occur in well-controlled studies
2. Probable: very likely, but not proven clinically
3. Suspected: may occur; some good data, but needs more study
4. Possible: could occur, but data are very limited
5. Unlikely: doubtful; no good evidence of a clinical effect
PDDIa
Figure 1. Classification of potential drug–drug interactions (Drug Interaction Facts). aPotential drug-drug interaction.
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(1.54–1.78); Po0.0001) and cancer type (genito-urinary cancer,
OR 0.25 (0.12–0.52); Po0.0001) remained statistically significant.
DISCUSSION
To our knowledge, this is the first study to investigate the
prevalence of PDDIs among cancer patients that are on oral
anticancer treatment. In this analysis, we detected a high
prevalence of PDDIs with 46% of all patients being exposed to at
least one PDDI. More importantly, these PDDIs were not just
theoretical in nature, 16% of all patients had at least one major
PDDI that may have had harmful side effects and which usually
would have needed intervention or intensive monitoring.
Most PDDIs (86%) were supported by level 2 or level 3 scientific
evidence. In the majority of PDDIs, a supportive care agent was
involved (86%). Potential drug–drug interactions with coumarins,
whose anticoagulant effects may be altered, and fentanyl, through
which plasma concentrations and toxicity of fentanyl may be
increased, were most frequently registered. This also counted for
drug combinations that may have led to QT-interval prolongation,
or to GI toxicities. The highest prevalence concerned CNS
interactions that accounted for up to 73% of all PDDIs.
The drug–drug combinations of coumarins with certain oral
anticancer agents (e.g., capecitabine) may result in altered antic-
oagulant effects and haemorrhage due to the increased hypopro-
thrombinemic effects of coumarins (Ritchie and Grant, 1989;
Nakajima et al, 2010; Shah et al, 2010). In case of a PDDI,
anticoagulant effects should be closely monitored and the dose of
coumarins must be adjusted accordingly. Combinations of strong
CYP3A4 iso-enzyme inhibitors/inducers and anticancer drugs can
be potentially harmful (Kehrer et al, 2002; Mathijssen et al, 2002).
In this study, the combination of fentanyl and strong CYP3A4 iso-
enzyme inhibitors (e.g., itraconazole) was frequently found. This
CYP3A4 inhibitor may decrease the metabolic elimination of this
opioid, resulting in increased plasma concentrations and pharma-
cologic effect of fentanyl. Closely monitoring for signs of excessive
narcotic effects of fentanyl is indicated and dosage reduction may
be required (Hallberg et al, 2006; Official package labelling Actiq
(fentanyl citrate), 2007).
Drug combinations that could lead to QT-interval prolongation,
or to GI toxicity, can have serious or even fatal consequences, like
torsade de pointes and NSAIDs induced ulcers, respectively
(Scientific Advisory Board of the Arizona Center for Education
and Research on Therapeutics (CERT); Piper et al, 1991;
Lanza, 1998). Due to the extensive use of QT-prolonging drugs
Table 1. Demographic characteristics
n %
Study population 898 100
Age in yearsa 61 (18–95) —
Sex
Female 518 57.7
Male 380 42.3
Hospital
Radboud University Medical Center 463 51.6
University Hospital Maastricht 362 40.3
Deventer Hospital 73 8.1
Cancer type
Solid malignancy 766 85.3
Haemato-oncology 132 14.7
Cancer type solid malignancy
Breast 273 30.4
Gastrointestinal (GI) 257 28.6
Genito-urinary (GU) 102 11.4
Neurological 79 8.8
Lung 28 3.1
Gynaecologic 13 1.4
Other 15 1.6
Cancer type haemato-oncology
Leukaemia 40 4.5
Myeloproliferative disease 36 4.0
Malignant lymphoma 32 3.5
Plasma cell dyscrasia 15 1.7
Myelodysplastic syndrome 8 0.9
Immunocytoma 1 0.1
No. of drugs used per patienta 5 (1–24) —
No. of drugs used per patient per groupa
Oral anticancer agents 1 (1–3) —
Supportive care drugsb 1 (0–9) —
Other 2 (0–17) —
No. of comorbidities per patienta,c 1 (0–8) —
Laboratory valuesa
Creatinine 72 (26–568) —
Aspartate aminotransferase 27 (4–1188) —
Alanine aminotransferase 23 (5–845) —
Gamma-glutamyltransferase 39 (8–1712) —
Total laboratory abnormalitiesd 110 12.2
aMedian (range).
bAntiemetics and pain medication.
cAs we retrospectively retrieved comorbidity data from the oncology patient files, the real
number of comorbidities could have been higher.
dBecause of missing data, the denominator is n¼ 690. Liver failure (94), kidney failure (14),
and combination (2).
Table 2. Oral anticancer drugs identified
Drug class
(ATC code) Drugs (n)
Oncolytics (L01)
Alkylating agents Temozolomide (75), Chlorambucil (34),
Cyclophosphamide (26), Lomustine (9), Melphalan (9),
Procarbazine (9), Busulfan (1)
Antimetabolites Capecitabine (258), Hydroxyurea (41), Fludarabine (9),
Mercaptopurine (8), Thioguanine (3), Uracil-Tegafur
(2), Methotrexate (1)
Protein kinase
inhibitors
Imatinib (30), Sunitinib (27), Erlotinib (10), Dasatinib
(9), Nilotinib (8), Sorafenib (4), Everolimus (4),
Thalidomide (1)
Topoisomerase
inhibitors
Etoposide(19), Topotecan (1)
Other oncolytics Tretinoin (3)
Antihormonal agents (L02)
Anti-oestrogens Tamoxifen (171)
Enzyme inhibitors Anastrozole (75), Letrozole (29), Exemestane (5)
Anti-androgens Bicalutamide (76), Flutamide(3)
Abbreviations: ATC code¼Anatomical Therapeutic Chemical code.
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(e.g., ondansetron) and drugs that can cause GI toxicity (e.g.,
NSAIDs) in (haemato)-oncology these PDDIs may cause sig-
nificant health risks. Concerning QT interactions, there is very
little information to guide clinicians about the risks of concomi-
tantly using QT-prolonging drugs, and how these PDDIs should be
managed. Moreover, the evidence for risk of Torsades de point is
often imperfect. Nevertheless, QT interactions are presumed to
have the potential for life-threatening consequences. Drug–drug
combinations that could lead to QT-interval prolongation or to GI
toxicity should, if possible, be avoided.
The high prevalence of CNS interactions is of particular
concern, since injuries resulting from balance disorders may have
a major impact on public health. The authors acknowledge that a
large number of cancer patients need CNS depressant medication
(e.g., opioids, antidepressants, and benzodiazepines). However, due
to the increased risk of osteoporosis and the extensive use of CNS-
depressant drugs, cancer patients are particularly at risk for
fractures (Gralow et al, 2009). Prescribed CNS-depressant drugs
can result in an up to 47% increased risk of falls (Landi et al, 2005).
Prescription of combinations of CNS-depressant drugs may even
further increase this risk (Hartikainen et al, 2005). Although
combinations of CNS-depressant drugs are often used for
therapeutic reasons, oncologists and other health-care profes-
sionals should minimise the number of CNS depressant drugs
prescribed, or at least carefully assess combinations of CNS-
depressant drugs and monitor for signs of balance disorders.
In this study, the number of drugs used concomitantly has been
identified as a risk factor for the occurrence of PDDIs. Genito-
urinary cancer showed a lower risk. It is not surprising that an
increasing number of drugs used is associated with an increased
risk of PDDIs and is in agreement with other studies (Riechelmann
et al, 2007; van Leeuwen et al, 2011). Patients with genito-urinary
cancers were less likely to be exposed to PDDIs. A plausible
explanation for this lower risk could be the relatively mild
interaction profile of bicalutamide, which was predominately used
for the oral treatment of prostate cancer in our studied population.
However, many medical centres still use flutamide and nilutamide
for the treatment of prostate cancer, which do have interacting
potentials. This questions the generalisability of prostate cancer as
a risk factor.
A great strength of this study was that the medication data in
the computer-based medication prescription system were based on
‘actual concurrent use’ (Tobi et al, 2007). If an oral anticancer drug
was dispensed in the hospital pharmacy, then the actual use of
other drugs (e.g., supportive care drugs’ and ‘drugs to treat
additional diseases/comorbidities’), both on a continuous base and
an incidental use, was always discussed with the patient and
registered in the computer-based medication prescription system.
Other strengths of our study included the large multicentre sample
size, cross-sectional design, use of a large variety of oral anticancer
agents, objective identification of PDDIs based on highly sensitive
screening software (Facts and Comparisons, version 4.0, 2006;
Barrons, 2004 and the additional screening for QT, GI, and CNS
interactions. These factors increase the validity and representa-
tiveness of this study.
A major limitation of this study is that it does not investigate the
clinical impact of the PDDIs. Although Buajordet et al (2001)
estimated that PDDIs are responsible for the death of 4% of
hospitalised cancer patients, insights into the clinical consequences
of PDDIs in cancer patients remains largely unknown and should
be further explored in prospective studies. Also, the true relevance
of some drug–drug interactions identified by Drugs Interaction
Level of severity
Total PDDIsa
n =1359
Drug interaction mechanism
Major (n =197)
2%
14%
84%
Moderate (n =1133)
Minor (n =29)
Level of scientific evidence
Established (n =0)
0%
5%
9%
10%
76%
73%
15%
4%
8%
Suspected (n =135)
Possible (n =125)
Unlikely (n =65)
Probable (n =1034)
CNS interactions (n =848)
GI interactions (n =97)
QT interactions (n =45)
Other PD-interactions (n =174)
PD interactions
n =1164
PK interactions
n =195
Figure 2. Prevalence, classification, and mechanism of potential drug interactions. aPotential drug-drug interactions.
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Facts software or the additional manual search may sometimes be
questioned (e.g., NSAIDs and bisphosphonates or NSAIDs and
SSRIs). Furthermore, it is not known to what extent precautions
(e.g., dosage adjustments) were taken by the health-care profes-
sionals to prevent potentially harmful PDDIs. Since these
precautions are not being accounted for in this study, this may
lead to an over-detection of PDDIs by electronic PDDI databases,
as was concluded by Chan et al (2011). Another limitation of this
study was that we did not study PDDIs between prescription drugs
and OTC medication. In our previous study (van Leeuwen et al
(2011)), OTC drugs were involved in 11% of all PDDIs. Although
drug combinations with OTC drugs were not investigated in this
study (due to the retrospective search in the computer-based
medication prescription system), PDDIs with OTC drugs are
relevant and can be potentially harmful (Mathijssen et al, 2002;
Tascilar et al, 2006).
Our findings were largely in accordance with other studies
(Riechelmann et al, 2007; van Leeuwen et al, 2011). Conversely, a
comparable retrospective database study, conducted in Eastern
cancer patients using oral anticancer therapy, found that only 5%
of all patients had at least one PDDI (Ko et al, 2012). A possible
explanation for the higher prevalence of PDDIs in our study may
be the additional search for QT, GI and CNS interactions.
Nevertheless, the existence of potentially harmful PDDIs should
not be neglected and needs the explicit attention of pharmacists
and medical doctors.
In conclusion, over the past years there has been a sharp shift
and focus towards oral anticancer drugs. The present study shows
that besides their possible benefits, cancer patients on oral
anticancer therapy are at considerable risk for PDDIs. It remains
unknown to what extent pharmacies and medical doctors were
actually aware of these PDDIs and whether they took adequate
measures to prevent potentially harmful drug–drug combination.
Therefore, the impact of the identified PDDIs on clinical outcomes
remains partly unknown and should be further investigated in
detail in future prospective studies. In the Erasmus University
Table 3. Major drug–drug interactions found in the database search
n Description Severity
Scientific
evidence
Potential drug–drug interactions involving anticancer agents
TamoxifenþOndansetron/Granisetron/Sotalol/Erythromycin/
Levofloxacin/Methadone/Risperidone/Azithromycina (Scientific
Advisory Board of the Arizona Center for Education and Research
on Therapeutics (CERT))
28 Drug combinations can prolong QT interval Major 2
CoumarinsþCapecitabine/Tamoxifen/Etoposide
(Ritchie and Grant, 1989; Shah et al, 2010)
17 Hypoprothrombinemic effects of coumarins may be
increased, bleeding may occur
Major 2
Methotrexateþ Sulfamethoxazole/Trimethoprim/Acetylsalicylic
acid (Bourre´-Tessier and Haraoui, 2010; Seideman, Mu¨ller-Suur,
1993)
12 Increased pharmacologic effects of methotrexate with an
increased risk of bone marrow and hepatic toxicity
Major 2
(Es)omeprazoleþDasatinib/Nilotinib (Yin et al, 2010) 4 Proton pump inhibitors may decrease the plasma
concentration of tyrosine kinase receptor inhibitors
Major 3
Methotrexateþ Prednisolone (Koerber et al, 1994) 2 Prednisolone may decrease the total clearance of
methotrexate
Major 2
MethotrexateþAmoxicillin/Clavunate (Zarychanski et al 2006) 1 Penicillins may decrease the total clearance of
methotrexate
Major 4
PerphenazineþTamoxifen (Sideras et al, 2010) 1 Pharmacologic effects of tamoxifen may be decreased by
Perphenazine. Co-administration may increase the risk of
breast cancer recurrence
Major 4
Potential drug–drug interactions involving supportive care drugs
NSAIDsbþCorticosteroids c/SSRIsd/Dipyridamole/Clopidogel/
Alendronate (Piper et al, 1991; Lanza, 1998)
98 Increased risk of GI bleeding Major 2
SSRIsþMetoclopramide/Tramadol (Fisher and Davis, 2002;
Houlihan, 2004)
16 Serotonin syndrome is a potential risk with this combination Major 4
FentanylþFluconazole/Aprepitant/Ketoconazole/Diltiazem/
Itraconazole (Hallberg et al, 2006; Official Packaged labelling for
Actiq, 2007)
12 Increased pharmacologic effects and plasma
concentrations of fentanyl
Major 2
HaloperidolþGranisetron/Metoclopramide
OfloxacinþMethadone (Scientific Advisory Board of the Arizona
Center for Education and Research on Therapeutics (CERT))
5 Drug combinations can prolong QT interval Major 2
FluconazoleþMethadone (Tarumi et al, 2002) 1 Increased plasma concentration and pharmacologic effects
of methadone
Major 4
Abbreviations: GI¼gastrointestinal; NSAIDs¼ non-steroidal anti-inflammatory drugs; PDDI¼potential drug–drug interaction; SSRIs¼ selective serotonin reuptake inhibitors.
aReferences in this table are only mentioned to clarify for the identification of a PDDI. For a comprehensive overview of all references, go to Facts&Comparisons (Facts and Comparisons,
version 4.0, 2006).
bNSAIDs: Acetylsalicylic acid, Diclofenac, Ibuprofen, Meloxicam, and Naproxen.
cCorticosteroids: Budesonide, Dexamethasone, and Prednisolone.
dSSRIs: (Es)citalopram, Fluoxetine, Paroxetine, and Venlafaxine.
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Medical Centre, a prospective clinical trial such as this is currently
ongoing, to explore important remaining questions. For instance,
the effects of duration of anticancer drug treatment and the dose of
the drugs that may interact will be studied in detail.
This is particularly relevant as with the increasing numbers of
new oral anticancer agents that become available, the risk for
PDDIs will consequently increase. Despite this fact, in current daily
practice medication review is not always common practice. We
realise that many combinations of interacting drugs are unavoid-
able and may be administered together if appropriate precautions
are taken (e.g., monitoring and dosage adjustment). However, this
requires a solid medication review of all drugs used at every patient
visit by an oncologist or pharmacist. Therefore, in an ideal
situation, all drugs prescribed by oncologists, general practitioners,
and other health-care professionals should be documented
electronically, including patient’s medical status, in computer-
based patient records to identify and prevent potentially harmful
PDDIs.
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